We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+31.07%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.97B
AUM Growth
+$63.5M
(+3.3%)
Cap. Flow
-$255M
Cap. Flow
% of AUM
-12.96%
Top 10 Holdings %
Top 10 Hldgs %
56.65%
Holding
39
New
5
Increased
6
Reduced
7
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$97.7M |
| 2 |
Ventas
VTR
|
+$47.1M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$43.3M |
| 4 |
Pediatrix Medical
MD
|
+$19.8M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$76.1M |
| 2 |
AbbVie
ABBV
|
+$37.9M |
| 3 |
Zymeworks
ZYME
|
+$37.2M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$36.2M |
| 5 |
DaVita
DVA
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.44% |
| 2 | Real Estate | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBIO
26
Crescent Biopharma
CBIO
$537M
| $18.5M | 0.94% |
35,000
| – | – |
|
|
TBIO
27
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $12.2M | 0.62% |
1,500,000
| – | – |
|
|
TECX
28
Tectonic Therapeutic
TECX
$529M
| $12.1M | 0.61% |
50,000
+8,333
| +20% | +$1.61M |
|
29
Sutro Biopharma
STRO
$401M
| $6.6M | 0.34% |
60,000
| – | – |
|
|
30
AbbVie
ABBV
$443B
| – | – |
-500,000
| Closed | -$37.9M |
|
|
31
Bristol-Myers Squibb
BMY
$133B
| – | – |
-1,500,000
| Closed | -$76.1M |
|
32
Cyclerion Therapeutics
CYCN
$14.9M
| – | – |
-111,353
| Closed | -$27M |
|
33
GSK
GSK
$104B
| – | – |
-400,000
| Closed | -$21.3M |
|
|
NVO
34
Novo Nordisk
NVO
$208B
| – | – |
-1,400,000
| Closed | -$36.2M |
|
35
Surgery Partners
SGRY
$2.01B
| – | – |
-160,084
| Closed | -$1.18M |
|
36
United Therapeutics
UTHR
$25.8B
| – | – |
-400,000
| Closed | -$31.9M |
|
|
37
Zymeworks
ZYME
$1.61B
| – | – |
-1,500,000
| Closed | -$37.2M |
|
|
WMGI
38
DELISTED
Wright Medical Group Inc
WMGI
| – | – |
-750,000
| Closed | -$15.5M |
|
|
AGN
39
CALL
DELISTED
Allergan plc
AGN
| – | – |
-500,000
| Closed | -$84.1M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Camber Capital Management held 39 positions worth $1.97B, up 3.3% from $1.9B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Camber Capital Management withdrew a net $255M in Q4 2019, closing 10 positions and reducing 7 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $76.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Real Estate.
Against the trend, Camber Capital Management opened a new position in Gilead Sciences worth $97.5M.
- Camber Capital Management's largest Q4 2019 buy was Gilead Sciences: 1,500,000 shares worth $97.5M.
- Camber Capital Management added most to Nektar Therapeutics in Q4 2019, an estimated $14.5M increase.
- Camber Capital Management's biggest Q4 2019 reduction was DaVita, cutting an estimated $33.2M.
- Camber Capital Management fully exited Bristol-Myers Squibb in Q4 2019, selling an estimated $76.1M.
- Camber Capital Management's ten largest holdings make up 57% of its $1.97B portfolio in Q4 2019.
- Camber Capital Management opened 5 new positions and closed 10 in Q4 2019.
- Camber Capital Management's portfolio value rose 3.3% quarter-over-quarter to $1.97B.
Based on Camber Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.